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Life-threatening pulmonary influenza can be caused by inborn errors of type I and III IFN immunity. We report a 5-yr-old 
child with severe pulmonary influenza at 2 yr. She is homozygous for a loss-of-function IRF9 allele. Her cells activate 
gamma-activated factor (GAF) STAT1 homodimers but not IFN-stimulated gene factor 3 (ISGF3) trimers (STAT1/STAT2/
IRF9) in response to IFN-α2b. The transcriptome induced by IFN-α2b in the patient’s cells is much narrower than that 
of control cells; however, induction of a subset of IFN-stimulated gene transcripts remains detectable. In vitro, the 
patient’s cells do not control three respiratory viruses, influenza A virus (IAV), parainfluenza virus (PIV), and respiratory 
syncytial virus (RSV). These phenotypes are rescued by wild-type IRF9, whereas silencing IRF9 expression in control 
cells increases viral replication. However, the child has controlled various common viruses in vivo, including respiratory 
viruses other than IAV. Our findings show that human IRF9- and ISGF3-dependent type I and III IFN responsive 
pathways are essential for controlling IAV.
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Introduction
Influenza virus is a common pathogen in children. It typically 
causes self-limiting respiratory disease, but can also cause severe 
illness with pneumonia and acute respiratory distress syndrome 
(ARDS; Short et al., 2014). Virus strain differences can influence 
the frequency and severity of infections, as illustrated by sea-
sonal epidemics and pandemics caused by new recombinant in-
fluenza viruses, but do not explain inter-individual variability in 
a given population infected by the same virus (Taubenberger and 
Morens, 2006, 2008; Writing Committee of the WHO Consulta-
tion on Clinical Aspects of Pandemic (H1N1) 2009 Influenza et al., 
2010). Few human risk factors have been identified and consist 
mostly of acquired comorbidities, such as chronic pulmonary 
or cardiovascular disease and old age (Palese and Shaw, 2007; 
Shieh et al., 2010; Dawood et al., 2011). Thus, the pathogenesis 
of life-threatening pulmonary influenza in individuals without 
preexisting cardiac or pulmonary disease remains largely unex-
plained, especially in children (Centers for Disease Control and 
Prevention, 2013). Recently, we described autosomal recessive 
(AR), complete IRF7 deficiency as the first genetic etiology for 
life-threatening influenza ARDS in otherwise healthy humans 
(Ciancanelli et al., 2015). The lack of IRF7-dependent type I and 
type III IFN amplification by plasmacytoid dendritic cells (pDCs) 
or pulmonary epithelial cells, or both, probably underlies this 
patient’s susceptibility to influenza. GATA2 haploinsufficiency 
is the only other known inborn error of immunity underlying 
severe influenza, albeit in patients with multiple infections. 
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Three patients had severe influenza at ages 18, 31, and 54 yr, as-
sociated with the abnormal development of multiple myeloid 
and lymphoid subsets, including pDCs (Sologuren et al., 2018). 
Influenza was the first severe infection in only one of these pa-
tients (Pasquet et al., 2013; Sole-Violan et al., 2013). The mech-
anism underlying severe influenza in GATA2-deficient patients 
is unknown, but might involve their lack of pDCs, which are 
among the most potent type I and type III IFN-producing cells 
due to their high basal expression of IRF7 (Coccia et al., 2004; 
Asselin-Paturel et al., 2005; Osterlund et al., 2007; Lauterbach et 
al., 2010; Ning et al., 2011). Intriguingly, inborn errors of TLR3- 
or MDA5-dependent production of IFNs have not been shown 
to underlie severe influenza (Zhang et al., 2007; Lamborn et al., 
2017). Interestingly, STAT1-, STAT2-, JAK1-, TYK2-, IFN AR2-, and 
IL10RB-mutated patients, with defective type I and/or III IFN 
responses, were not reported to suffer from severe influenza 
(Glocker et al., 2009; Begue et al., 2011; Boisson-Dupuis et al., 
2012; Hambleton et al., 2013; Duncan et al., 2015; Kreins et al., 
2015; Shahni et al., 2015; Eletto et al., 2016; Moens et al., 2017). 
Moreover, patients with any of the >350 other known inborn er-
rors of immunity, including patients lacking T cells, or B cells, 
or both, have not been reported to suffer from severe influenza 
(Bousfiha et al., 2018; Picard et al., 2018). Collectively, these data 
suggest that the human GATA2- and IRF7-dependent production 
of type I and/or type III IFNs is essential for protective immunity 
against influenza virus.
Mice either homozygous for an Irf7-null allele or heterozy-
gous for a Gata2-null allele have also been characterized. Al-
though Gata2+/− mice were found to possess significantly reduced 
pDC counts, they have not been studied for infectious diseases, 
as research has instead focused on hematopoietic and vascular 
integrity (Johnson et al., 2012; Collin et al., 2015; Onodera et al., 
2016). Similarly, the integrity and function of the type III IFN 
signaling pathway remains largely unexplored in Gata2+/− mice. 
Irf7−/− mice display reduced induction of IFN-α/β following ei-
ther viral infection or stimulation with synthetic TLR agonists, 
as well as increased vulnerability to infection with HSV-1 and en-
cephalomyocarditis virus (Sato et al., 1998; Honda et al., 2005). 
More recently, Irf7 was identified as one of 25 differentially ex-
pressed genes between C57BL/6J and DBA/2J mice infected with 
influenza A virus (IAV) that overlapped with differentially ex-
pressed genes identified in other siRNA screens to be important 
for IAV replication (Wilk et al., 2015). Furthermore, Irf7−/− mice 
that were derived on a C57BL/6 background that does not con-
tain a functional Mx1 allele, when infected by influenza virus, 
experienced greater morbidity and mortality than control mice 
(Wilk et al., 2015). Most other studies analyzing the genetics and 
immunology of influenza infection have also been performed in 
Mx1-deficient mice and thus should be reexamined in mice ex-
pressing Mx1, due to the crucial role of this IFN-stimulated gene 
(ISG) product in mouse immunity to influenza virus (Staeheli et 
al., 1988; Iwasaki and Pillai, 2014; Ciancanelli et al., 2016). Sig-
nificantly, however, Ifnb1−/− mice are substantially more sen-
sitive to IAV, even in an Mx1-positive background (Koerner et 
al., 2007). Similar studies in an Mx1-positive background have 
demonstrated crucial roles for IFN AR1, TLR7, and MyD88 signal-
ing in defense against influenza infection (Koerner et al., 2007; 
Kaminski et al., 2012). Mice with impaired type III IFN immunity 
have been shown to display marginally elevated influenza virus 
replication relative to WT mice, and to be hypersensitive to influ-
enza virus when type I IFN signaling was also ablated (Mordstein 
et al., 2008). Overall, type I and/or type III IFN immunity seem 
to be crucial for protective immunity against influenza virus in 
both humans and mice. Not all inborn errors of human type I 
and III IFN immunity, however, underlie severe influenza, at least 
among the few human patients reported. We therefore hypothe-
sized that defects of type I and III IFNs other than GATA2 and IRF7 
deficiency may underlie severe influenza in other individuals. 
Thus, we set out to analyze the whole-exome sequencing (WES) 
data of 20 children with severe influenza by first focusing on 
type I and III IFN-related genes.
Results
Homozygosity for a splice site mutation in IRF9
We studied a 5-yr-old girl (patient [P]) born to first-cousin Alge-
rian parents and living in France who was hospitalized for severe 
infection with IAV requiring mechanical ventilation and Tami-
flu treatment, and who had a history of recurrent benign bron-
chiolitis, biliary perforation following measles-mumps-rubella 
(MMR) vaccination at 1 yr of age, and recurrent fevers without a 
causative pathogen identified (Fig. 1 A). P also was infected with 
respiratory syncytial virus (RSV) within her first year of life, 
for which she was hospitalized but not admitted to the intensive 
care unit (ICU). We characterized P’s history of viral infections 
at age 2 yr, 7 wk before IgG i.v. substitution and after maternal 
antibodies disappeared, by VirScan (Xu et al., 2015). We detected 
significant specific antibodies in P’s serum against many other 
viruses, including HSV-1, human cytomegalovirus, human rhi-
novirus (HRV), and enterovirus, in addition to confirming in-
fections with RSV and IAV (Fig. S1). After her recovery from IAV 
infection, she experienced adenovirus and parainfluenza virus 
(PIV) infections, both of which were also confirmed by VirScan. 
She was admitted to the hospital for these infections, but neither 
required admission to the ICU. We performed WES on this kin-
dred (trio design) and identified a c.991G>A mutation in IRF9, 
encoding a critical element of the type I and III IFN signaling 
pathways (IRF9), which was confirmed by Sanger sequencing 
(Fig. 1 B; Fu et al., 1990; Veals et al., 1992; Kimura et al., 1996). P 
was homozygous for this mutation while both parents and her 
healthy sister were heterozygous, a familial segregation consis-
tent with an AR pattern of inheritance with complete penetrance 
(Casanova et al., 2014). This variation was absent from public 
databases, including 1,000 genomes, Bravo, and Genome Aggre-
gation Database (GnomAD)—a database that encompasses the 
exome aggregation consortium (ExAC) database. This mutation 
occurs in the final nucleotide of exon 7 and is predicted to disrupt 
the essential splice site at the boundary of exon 7 and intron 7, 
as well as to produce an aspartic acid to asparagine mutation at 
amino acid 331 (p.D331N). Because of the different predictions 
for these mutations on IRF9 protein structure, we will presently 
refer to this allele by its effect on the cDNA, c.991G>A. The com-
bined annotation-dependent depletion (CADD) score of this vari-
ant was high, above the mutation significance cutoff (Fig. 1 C), 
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Figure 1. A private IRF9 variant alters mRNA splicing 
in a child with severe influenza pneumonitis. (A) Ped-
igrees of the IRF9-deficient family. The double lines con-
necting the parents indicate consanguinity. The proband 
is indicated by an arrow. Filled shapes indicate affected 
individuals while open shapes identify unaffected individu-
als. (B) Chromatograms demonstrating c.991G>A mutation 
in patient PBMC-derived DNA (red arrow). (C) Population 
genetics of homozygous coding missense and predicted 
loss-of-function IRF9 mutations taken from GnomAD and 
in-house cohorts. The patient’s variant is private and shown 
in red, while two other variants, shown in blue, were also 
identified in our cohort. (D) Schematic illustration of the 
IRF9 gene. The exons are numbered 1–9, and regions cor-
responding to functionally significant domains are colored 
brown (for the DNA-binding domain, DBD), gray (nuclear 
localization sequence, NLS), or purple (IAD). Patient muta-
tion indicated in red; other mutations indicated in blue. 
(E) IRF9 transcripts (left panel) and relative frequencies 
(right panel) produced during exon trapping in U2A cells. 
The results are representative of two independent experi-
ments. (F) cDNA sequencing to detect the splicing of IRF9 
mRNA from F-SV40 cells. Numbers of total and abnormal 
clones sequenced are indicated. Results representative of 
two experiments.
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Figure 2. Impact of IRF9 Δex7 on IFN receptor-proximal signaling. (A) qRT-PCR measuring of IRF9 mRNA levels in PBMCs from the patient, her mother, 
and a healthy control with two probes—one probe spanning intron 7, and a second probe spanning intron 1. Representative results of four independent exper-
iments are shown. (B) Top: WB of endogenous IRF9 in patient F-SV40 cells; GAP DH was used as a loading control. Bottom: STAT and phospho-STAT (pSTAT) 
levels were also assessed following stimulation with 1,000 U/ml of either IFN–α2b or –γ for 0.5 h on F-SV40 cells from two healthy controls (C1 and C2), the 
IRF9-deficient patient (IRF9−/−), her mother (IRF9+/−), a STAT1-deficient patient (STAT1−/−), a STAT2-deficient patient (STAT2−/−), an IFN GR2-deficient patient 
(IFN GR2−/−), and an IRF7-deficient patient (IRF7−/−). Representative results of five independent experiments are shown. (C) WB of IRF9 in IRF9-deficient U2A 
cells stably transfected with indicated variants (green: variants reported to be loss-of-function in in vitro assays, blue: variants found in-house, red: patient). 
GAP DH was used as loading control. Representative results of four independent experiments are shown. (D) WB of IRF9 in patient F-SV40 cells stably trans-
fected with indicated variants. GAP DH was used as loading control. Representative results of four independent experiments are shown. (E) WB analysis of 
IRF9 localization in F-SV40 cells from two healthy controls (C1 and C2), the IRF9-deficient patient (IRF9−/−), her mother (IRF9+/−), a STAT1-deficient patient 
(STAT1−/−), a STAT2-deficient patient (STAT2−/−), an IFN GR2-deficient patient (IFN GR2−/−), and an IRF7-deficient patient (IRF7−/−). GAP DH and LaminA/C were 
used as loading controls. Representative results of three independent experiments are shown. (F) Reporter assays of ISRE or GAS-dependent firefly luciferase 
tested in U2A cells stimulated with 1,000 U/ml of either IFN-α2b or -γ for 16 h after being stably transfected with indicated variants (green: variants reported 
to be loss-of-function in in vitro assays, blue: variants found in-house, red: patient). The specific response to IFN stimulation was calculated by the ratio of 
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further suggesting that it is deleterious (Kircher et al., 2014; 
Itan et al., 2016). Finally, P’s exome showed 6.8% homozygosity, 
consistent with her parents being first cousins (Belkadi et al., 
2016). Consistently, homozygous nonsynonymous rare variations 
(minor allele frequency <0.01) were also found in 19 other genes, 
none of which is a known disease-causing gene. Genes encoding 
topoisomerase 2A (TOP2A) and 5′-3′ exoribonuclease 2 (XRN2), 
the only two connected to known primary immunodeficiency 
(PID) genes in a connectome analysis, carried variants that were 
missense (Itan et al., 2013). The only three genes that carried 
homozygous variations predicted to be loss-of-function were 
unrelated to PIDs: disheveled binding antagonist of β catenin 2 
(DACT2), ENTH domain containing 1 (ENT HD1), and Forssman 
glycolipid synthase-like protein (GBGT1). Overall, these data 
suggested that P had AR IRF9 deficiency and that homozygosity 
for c.991G>A was the most plausible genotype responsible for 
severe influenza.
Population genetics of human IRF9
IRF9 encompasses 9 exons, including eight protein-coding exons 
(exons 2 through 9; Fig. 1 D). Although the gene damage index of 
IRF9 is moderate (1.16), its McDonald-Kreitman neutrality index 
of 0.088 indicates that it is under negative selection (Itan et al., 
2015). Consistently, only one nonsynonymous exonic and two in-
tronic variants were found in homozygosity in GnomAD, includ-
ing whole-exome and whole-genome sequences: c.381G>C:p.
Q127H, c.991+119T>G, and c.991+189C>A, with minor allele fre-
quencies of 0.001, 0.01, and 0.001, respectively. All three vari-
ants were present in our in-house WES cohort of 4,892 patients 
with severe infectious diseases, with the two intronic variants 
found in the heterozygous state in multiple individuals and the 
Q127H variant found in the homozygous state in one individual. 
Only one of the three variants was predicted to alter protein se-
quence and may therefore impact IRF9 function. The latter two 
mutations occur in an intron, are not predicted to create a splice 
site, and actually do not create a splice site (data not shown). 
The Q127H allele exists in our cohort in the homozygous state 
in an individual who suffered from a nonviral infection of the 
brain. Furthermore, analysis of our in-house WES cohort re-
vealed a third homozygous nonsynonymous variation in IRF9, 
c.874C>T:p.R292C, which was not found in public databases 
(Fig. 1 C). The individual harboring this variant also possessed 
a homozygous mutation in HOIL1 that underlied chronic au-
toinflammation, invasive bacterial infections, and muscular 
amylopectinosis, and he also experienced profound human 
cytomegalovirus viremia (Boisson et al., 2012). Homozygosity 
for any of the three exonic nonsynonymous variants (Q127H, 
R292C, and c.991G>A) is predicted to affect <1/10,000 individu-
als, which is not more common than severe influenza. The CADD 
scores of these three variants were all above the mutation sig-
nificance cutoff, indicating that they may impact the function of 
IRF9 (Fig. 1 C; Itan et al., 2016). We therefore set out to assess the 
consequences of P’s variant on IRF9 function (c.991G>A), as well 
as the two other IRF9 missense alleles found in homozygosity in 
other, rare individuals from the general population (Q127H) or 
our in-house cohort (R292C).
Expression of a truncated mRNA and protein by the 
mutant IRF9 allele
Because the c.991G>A mutation occurs at an essential splice site 
at the terminal nucleotide of exon 7, we hypothesized that it 
would produce an aberrantly spliced transcript. We thus tran-
siently transfected a segment of P’s allele encompassing introns 
5 through 8, as well as a segment from an identical region of 
a WT allele, into IRF9-deficient U2A fibrosarcoma cells, a gift 
from S. Pellegrini (Institut Pasteur, Cytokine Signaling Unit, INS 
ERM, Paris, France; Fig. S2; John et al., 1991). Sequencing of the 
resulting cDNAs revealed two transcripts produced from P’s IRF9 
allele (Fig. 1 E). The dominant transcript exhibited absence of 
exon 7 with normal exons 6 and 8. The second, minor transcript 
also lacked exon 7 but used an alternative splice acceptor site in 
exon 8. The segment from a WT allele, however, produced four 
different transcripts. One transcript demonstrating correct 
splicing at exons 6/7 and 7/8 junctions and a second transcript 
lacking exon 7 but correctly using the splice sites in exons 6 and 
8 were the dominant products. Two rare transcripts were also 
observed: one was a product of an alternative splice acceptor 
site in intron 5, whereas another resulted from an alternative 
splice acceptor site in exon 7 (Fig.  1  E). Only correctly spliced 
transcripts were observed in healthy control B-LCLs (EBV-trans-
formed B lymphoblastoid cell lines) and SV40 large T antigen 
immortalized fibroblasts (F-SV40 cells), suggesting that the two 
alternative transcripts observed in the overexpression setting 
are not present endogenously. Moreover, cDNA sequencing of P’s 
B-LCLs and F-SV40 cells did not reveal any transcript that would 
result in a D331N variant protein, as all transcripts lacked exon 7 
(Fig. 1 F). This mutant transcript (and the corresponding allele) 
will thus hereafter be referred to as IRF9-Δex7, as the deletion is 
in-frame and does not introduce a premature stop codon. Next, 
we evaluated IRF9 expression in P’s peripheral blood mono-
nuclear cells (PBMCs) and F-SV40 cells. Consistent with the 
results of our cDNA sequencing, only IRF9 transcripts lacking 
exon 7 were detected in P’s PBMCs, and a reduced number of 
full-length IRF9 transcripts were detected in both individuals 
harboring the c.991G>A mutation in proportion to the dosage of 
this allele (Fig. 2 A). By Western blotting (WB), a polyclonal anti-
body detected a truncated IRF9 species in both P’s cells and those 
of her mother, whereas full-length IRF9 was not detected in P’s 
cells (Fig. 2 B). The molecular weight of this truncated protein 
is roughly 12 kD lower than WT IRF9, consistent with a lack of 
exon 7 (142 amino acids), which forms a substantial portion of 
firefly luciferase reporter gene activity to constitutively expressed renilla luciferase activity (RLU, relative luciferase ratio). Representative results of three 
independent experiments are shown. (G) EMSA analysis of ISRE and GAS binding by IFN-stimulated B-LCLs from three healthy controls (C1, C2, and C3), the 
IRF9-deficient patient (IRF9−/−), her mother (IRF9+/−), a STAT1-deficient patient (STAT1−/−), a STAT2-deficient patient (STAT2−/−), and an IRF7-deficient patient 
(IRF7−/−). Representative results of three independent experiments are shown.
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Figure 3. Impaired ISG induction in IRF9-deficient cells. (A) Transcription levels of MX1, IFIT1, IFIT3, and CXCL9 assessed by qRT-PCR on F-SV40 cells 
treated with 1,000 U/ml of IFN–α2b, -β, or –γ for 2 h. Cells were from three healthy controls (C1, C2, and C3), an IRF9-deficient patient (IRF9−/−), her mother 
(IRF9+/−), and STAT1-deficient (STAT1−/−), STAT2-deficient (STAT2−/−), IRF7-deficient (IRF7−/−), and IFN GR1-deficient (IFN GR1−/−) patients. Representative results 
of four independent experiments are shown. (B and C) WB of MX1 and IFIT3 on F-SV40 (B) or B-LCL (C) cells treated with 1,000 U/ml of IFN–α2b for various 
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the IRF association domain (IAD) where STAT proteins interact 
with IRF9 (Fig. 1 D). Overall, these findings showed that the pa-
tient had AR IRF9 deficiency.
Normal activation of STAT1 and STAT2 in cells 
expressing mutant IRF9
We then studied the function of the mutated IRF9 protein, first 
focusing on the proximal signaling events in the IFN responsive 
pathway. To assess the expression of P’s mRNAs, plasmids en-
coding IRF9-Δex7 and the other two missense mRNAs found in 
homozygosity in other individuals (Q127H, R292C), or WT IRF9, 
were first stably transfected into U2A cells, and IRF9 expression 
was verified by WB (Fig. 2 C). The K81R and R292Q alleles were 
included throughout the study since they have been reported to 
be loss-of-function in in vitro studies due to impaired interaction 
with IFN AR2 (R292Q) or impaired ISG up-regulation (K81R; Tang 
et al., 2007). All IRF9 alleles were expressed at comparable levels, 
indicating that these variants can be normally transcribed and 
translated, and that the encoded mRNAs and proteins are stable in 
these conditions (Fig. 2 C). We found that STAT1 and STAT2 phos-
phorylation was normal in cells transfected with all alleles follow-
ing stimulation with type I IFN (not shown). Stable transfection of 
WT IRF9 in P’s F-SV40 cells restored normal expression of IRF9, 
suggesting that the poor expression of IRF9 in her cells was due to 
the homozygous Δex7 mutation in IRF9 (Fig. 2 D). STAT1 and STAT2 
were normally phosphorylated in P’s cells immediately following 
stimulation with type I IFN, suggesting that IRF9 is dispensable 
for this process (Fig. 2 B). These data are consistent with previous 
reports and our own findings that STAT1 and STAT2 phosphory-
lation occurs immediately following IFN stimulation of U2A cells 
(Jaworska et al., 2010; Arimoto et al., 2017). Thus, the Δex7 IRF9 
allele produces a truncated IRF9 protein that does not affect IFN 
AR-proximal signaling, in terms of STAT1 and STAT2 phosphor-
ylation, at least in SV40 fibroblasts and U2A fibrosarcoma cells.
Abolished activation of ISGF3 in cells expressing mutant IRF9
IRF9 participates in the formation of the ISGF3 transcription 
factor by binding with STAT1 and STAT2 via its IAD. IRF9 also 
enables binding of the trimer to DNA, after its translocation to 
the nucleus (Veals et al., 1993; Darnell et al., 1994; Taniguchi et al., 
2001; Stark and Darnell, 2012). Because P’s IRF9 protein deletion 
occurs in the IAD region (Fig. 1 D), we hypothesized that IRF9-
Δex7 may be unable to engage with STAT1 and STAT2 to form a 
functional ISGF3, consistent with a recent report of this domain’s 
function (Rengachari et al., 2018). To test this, we first fraction-
ated nuclear and cytoplasmic compartments of P’s F-SV40s under 
basal conditions to determine the localization of P’s IRF9 protein 
(Fig. 2 E). Consistent with the presence of a nuclear localization 
sequence in the N-terminus of IRF9, a small amount of IRF9 was 
visible in the nucleus even under basal conditions. IRF9-Δex7, 
although expressed at substantially lower levels than the full-
length protein, is also visible in the nucleus. Consistently, U2A 
cells transfected with IRF9-Δex7 exhibited abolished luciferase 
transcription when luciferase production was driven from an 
IFN-stimulated response element (ISRE) promoter, but normal 
transcriptional activity when it was driven by a gamma activa-
tion sequence (GAS) promoter (Fig. 2 F). In contrast, the Q127H 
and WT variants were able to induce transcription of lucifer-
ase from both ISRE and GAS promoters. Both R292Q and R292C 
variants displayed an intermediate phenotype with roughly 50% 
activity compared with the WT allele, suggesting that they are 
hypomorphic. Taken together, these data strongly suggest that 
P’s IRF9 variant, Δex7, is unable to encode an IRF9 protein that 
forms a functional ISGF3 transcription factor, while R292C is hy-
pomorphic and Q127H is neutral. Electrophoretic mobility shift 
assays (EMSAs) confirmed that P’s cells were not able to form 
a functional ISGF3 complex following IFN-α2b stimulation, as 
evidenced by abolished ISRE binding in vitro, although her cells 
were able to form gamma-activated factor complexes and bind 
GAS elements under the same conditions (Fig. 2 G). The patient 
is therefore most likely homozygous for a null IRF9 allele, as IRF9-
Δex7 was the only transcript detected in the cells tested. How-
ever, one cannot exclude the remote possibility that the splicing 
defect is leaky in untested cells, where residual D331N expression 
might result in a severe but not complete form of IRF9 deficiency.
IRF9 deficiency impairs induction of ISGs
Due to the inability of P’s cells to form functional ISGF3, we hy-
pothesized that her cells would display a profound inability to 
up-regulate ISGs following IFN stimulation. In contrast to con-
trol cells, P’s F-SV40s and B-LCLs did not substantially up-reg-
ulate MX1, IFIT1, or OAS1 expression in response to type I IFN, 
as assessed by quantitative RT-PCR (qRT-PCR) and WB (Fig. 3, 
A–D). Stable transfection of P’s F-SV40 cells with WT IRF9 was 
able to rescue the impaired induction of ISGs (Fig. 3 E). Simi-
larly, U2A cells stably transfected with Δex7 were not able to in-
duce transcription of either classic ISG, compared with WT IRF9 
(Fig. 3 F). CXCL9 expression was used throughout these qRT-PCR 
experiments to demonstrate the ability of all cells to respond 
to type II IFN. However, the response to type I IFN is substan-
tially broader than four or five genes, with potentially hundreds 
of genes displaying altered expression levels (Mostafavi et al., 
2016). To characterize fully the transcriptional responses of P’s 
cells to type I IFN, we performed mRNA sequencing (mRNA-seq) 
time points. GAP DH was used as a loading control. Representative results of three independent experiments are shown. (D) Transcription levels of MX1, IFIT1, 
IFIT3, and CXCL9 assessed by qRT-PCR of B-LCL cells treated with 1,000 U/ml of IFN–α2b, -β, or –γ for 2 h. Cells were from three healthy controls (T1, T2, 
and T3), an IRF9-deficient patient (IRF9−/−), her mother (IRF9+/−), and STAT1-deficient (STAT1−/−), STAT2-deficient (STAT2−/−), IRF7-deficient (IRF7−/−), and IFN 
GR2-deficient (IFN GR2−/−) patients. Representative results four independent experiments are shown. (E) Transcription levels of MX1, IFIT1, and CXCL9 assessed 
by qRT-PCR in F-SV40 cells from a healthy control (C1), P’s mother (IRF9+/−), and P (IRF9−/−) stably transfected with luciferase as a control (Luc) or indicated 
IRF9 variants (WT: WT IRF9, green: reported loss-of-function variants, blue: variants found in-house, red: patient variant). Cells were stimulated with 1,000 
U/ml of IFN-α2b, -β, or -γ for 2 or 8 h. Representative results of four independent experiments are shown. (F) Similar to E, qRT-PCR analysis of MX1, IFIT1, 
and CXCL9 expression in parental HT1080 cells and U2A cells. Cells were stimulated with 1,000 U/ml of IFN-α2b, -β, or -γ for 2 or 8 h. Representative results 
of three independent experiments are shown.
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analysis of P’s B-LCL cells and primary fibroblasts following in 
vitro stimulation with IFN-α2b. P’s B-LCL cells (Fig.  4, B and 
D–G) and primary fibroblasts (Fig.  4, A, C, and E–G) demon-
strated an inability to regulate a broad array of genes, including 
ISGs but also negatively regulated transcripts (data not shown). 
However, the response in P's cells was not abolished altogether. 
Indeed, out of all transcripts that passed our filter criteria for 
being IFN-α2b–regulated in P's B-LCL cells and primary fibro-
blasts, 118 and 267 transcripts, respectively, were also found to be 
regulated by IFN in the Interferome database v2.01 (Fig. 4, C and 
D). Furthermore, many of the up-regulated ISGs were signifi-
cantly less induced than those same ISGs were in healthy control 
cells (Fig. 4, E and F). Interestingly, however, some ISGs actually 
were induced at higher levels in IRF9-deficient cells when com-
pared with healthy controls (Fig. 4, E and F). Furthermore, these 
difference were not necessarily due to a reduction in basal tran-
script levels, since, of those genes that are more highly induced 
in IRF9-deficient cells, roughly 40% exhibit higher absolute 
transcript levels in the IRF9-deficient cells (data not shown). To 
further dissect the ISG network and dysregulation in P's B-LCL 
cells, we selected a subset of 84 transcripts that were strongly 
induced (greater than fivefold linear scale) by IFN-α2b among 
the healthy control subjects in our study. Of these transcripts, 37 
were found to be induced (>1.5-fold) and 47 were nonresponsive 
in P's B-LCL cells. The transcripts were then queried for ISGs 
in the Interferome v2.01 database, again using a 1.5-fold cut-
off to differentiate between IFN-responsive and nonresponsive 
genes. Of these 37 responsive and 47 nonresponsive transcripts 
in P's cells, 24 and 39 transcripts, respectively, were identified 
as ISGs in the Interferome v2.01 database. These were used for 
a ISG response network analysis using GeneMAN IA (Fig. 4 G). 
Notable ISGs that were not induced in P’s cells include genes 
encoding IFIT family proteins, ISG15, and components of the 
ISGylation system (USP18, HERC5). Consistent with the pres-
ence of ISGF3-independent transcription factors such as phos-
phorylated STAT1 homodimers downstream of the IFN receptor, 
however, mRNA of other important ISGs, such as DDX58, those 
for guanylate-binding proteins (GBP1, GBP4, and GBP5), ISG20, 
and STAT2, were induced by IFN-α2b in P’s cells, albeit for most 
genes to lower levels when compared with control subjects. The 
type III IFN responsive pathway cannot easily be studied in F-
SV40s and B-LCLs (Kreins et al., 2015). Collectively, our studies 
indicate that P’s cells express a loss-of-function IRF9 allele that 
severely narrows the transcriptional responses to type I IFN in 
multiple cell types, with functional gamma-activated factor but 
a lack of ISGF3 complexes resulting in the induction of a small 
subset of ISGs.
Impaired anti-viral immunity in the patient’s fibroblasts
We investigated the impact of IRF9 deficiency on cell-intrinsic, 
nonhematopoietic immunity, using P’s F-SV40 cells. We ob-
served an ∼10-fold difference in IAV titer at 48 h after infection 
when compared with healthy controls and P’s heterozygous 
mother (Fig.  5  A). Pre-treatment with IFN-α2b substantially 
reduced viral replication in healthy control cells but not P’s 
cells, which produced roughly 100-fold higher IAV titers than 
cells with an intact IFN signaling pathway (Fig. 5 A). Similarly, 
P’s F-SV40s were substantially more susceptible to vesicular 
stomatitis virus (VSV) at 12 h after infection in the absence of 
pretreatment with IFN-α2b, or at all time points beyond 8 h in 
cells that were pretreated with IFN, with roughly a 1,000-fold 
difference in titer between healthy controls and P (Fig. 5 B). To 
demonstrate that these defects in IAV and VSV immunity were 
IRF9 dependent, we stably transfected P’s F-SV40 cells with var-
ious IRF9 alleles or an empty vector and analyzed the ability of 
the transfected cells to control VSV and IAV infection (Fig. 5, C 
and D). Expression of WT IRF9 was able to rescue the inability 
of P’s cells to control of infection with either pathogen, while 
expression of K81R and IRF9-Δex7 alleles was unable to do so. 
Significantly, cells that expressed the Q127H mutation were also 
able to control infection with VSV or IAV, suggesting that this 
allele may not be deleterious in the context of type I IFN signal-
ing and anti-viral immunity, consistent with the lack of overt 
viral infections experienced by the individual harboring this 
mutation. R292Q and R292C alleles were also somewhat able to 
control infection with VSV or IAV, although not at the level of the 
WT IRF9 allele, suggesting that a partial form of IRF9 deficiency 
may have contributed to the viral infections of the HOIL1-de-
ficient patient (Boisson et al., 2012). We further showed that 
cell-intrinsic anti-viral immunity was broadly impaired, by 
testing PIV and RSV (Fig. 5, E–H). To further demonstrate that 
IRF9 mediates susceptibility to viral infection in vitro, we also 
knocked down IRF9 or mitochondrial anti-viral signaling pro-
tein (MAVS) expression in primary dermal fibroblasts from 
Figure 4. Transcriptomic analysis of ISGs in IRF9-deficient cells. mRNA-seq analysis of primary fibroblasts (A and C) and B-LCLs (B and D) from three 
healthy controls (C1, C2, and C3), the IRF9-deficient patient (IRF9−/−). Cells were treated with 1,000 U/ml IFN–α2b for 2 h. Heatmaps (A and B) show log2 
FC values of all ISGs that were found to be differentially regulated (≥1.5-fold) in all three control subjects relative to unstimulated cells. Bar graphs (C and D) 
quantify the number of ISGs that were differentially regulated (≥1.5-fold) compared with unstimulated cells in healthy controls or the IRF9-deficient patient. 
(E) Shown are Δ log2 fold change values of a subset of ISGs that were found to be induced ≥1.5-fold (linear scale) in B-LCL cells (upper panels) or primary 
fibroblasts (lower panels) of the IRF9-deficient patient upon in vitro stimulation with IFN-α. To select this subset of ISGs, the IFN-α2b–induced genes in the 
healthy controls identified in the mRNA-seq analysis were used. In the IRF9-deficient patient, these genes were first passed through a filter by querying the 
gene identifiers against the interferome database and by retaining genes that were responsive to in vitro IFN stimulation. ISGs that failed to be induced at 
least 1.5-fold (linear scale) in patient cells were excluded. The retained ISGs were stratified in three groups of less (Δ less than −0.585), similar (−0.585 < Δ < 
0.585), and higher (Δ > 0.585) induced genes relative to the average responses in the healthy control subjects. The numbers of genes in each group are shown 
in brackets. ***, significant differences at P < 0.0001 by the Kruskal-Wallis test. (F) Log2 FC of induced ISGs in IRF9-deficient B-LCLs (upper panels) or primary 
fibroblasts (lower panels) and their corresponding values in healthy donors. (G) Network analysis of a subset of highly inducible (> fivefold linear scale) ISGs 
among control subjects’ B-LCLs and their responsiveness in the IRF9-deficient patient. Biological pathway and physical interactions are depicted as blue and 
red lines, respectively. 1.5 FC was used as the cut-off to distinguish responsive (red circle) and nonresponsive (blue circle) ISGs. The highly inducible ISGs that 
were used for query are shaded in yellow.
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Figure 5. Crippled control of IAV and other viral infections in IRF9-deficient cells. (A) IAV titers in F-SV40 unstimulated (left) or pretreated (right) with 
1,000 U/ml IFN-α2 for 16 h, followed by infection with (A/H1N1/CA/2009) IAV at MOI = 1. Mean ± SD (n = 3) is shown. Cells from three healthy controls were 
included (C1, C2, and C3), as well as those from the IRF9-deficient patient (IRF9−/−), her mother (IRF9+/−), and STAT1-deficient (STAT1−/−), STAT2-deficient 
(STAT2−/−), and IRF7-deficient (IRF7−/−) patients. Four independent experiments (mean ± SD) are shown. (B) VSV titers in F-SV40 cells unstimulated (left) 
or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with VSV at MOI = 3. Four independent experiments (mean ± SD) are shown. (C) 
IAV titers in stably transfected F-SV40 cells unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed by infection with IAV at MOI 
= 1. Cells were from a healthy control (C1), a STAT1-deficient patient (STAT1−/−), P (IRF9−/−), and P’s cells stably transfected with luciferase or WT IRF9 (gray), 
variants reported to be loss-of-function in in vitro assays (green), variants found in-house (blue), or the patient’s variant (red). Three independent experiments 
(mean ± SD) are shown. (D) VSV titers in stably transfected F-SV40 cells unstimulated (left) or pretreated (right) with 1,000 U/ml IFN-α2 for 16 h, followed 
by infection with VSV at MOI = 3. Four independent experiments (mean ± SD) are shown. (E) Percentage of RSV-infected (GFP+) F-SV40 cells at 24 and 48 h 
after infection. Cells from three healthy controls were included (C1, C4, and C5, black), as well as those from the IRF9-deficient patient (IRF9−/−, red), and cells 
from STAT1-deficient (STAT1−/−), STAT2-deficient (STAT2−/−), and IRF7-deficient (IRF7−/−) patients. Three independent experiments (mean ± SD) are shown. 
(F) Mean fluorescence intensity (MFI) of RSV-infected (GFP+) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are 
shown. (G) Percentage of PIV-infected (GFP+) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are shown. (H) MFI of 
PIV-infected (GFP+) F-SV40 cells at 24 and 48 h after infection. Three independent experiments (mean ± SD) are shown. MFI of GFP+ cells in individual samples 
were normalized to the averaged MFI of the three healthy controls at 24 h after infection in F and H.
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healthy individuals using siRNA, or transfected these cells with 
a nontargeting siRNA (siNeg) instead (Fig.  6  A). Knockdown 
of either IRF9 or MAVS resulted in increased viral transcripts 
compared with siNeg cells upon infection with HRV, suggesting 
that IRF9 is nonredundant for immunity to positive-sense RNA 
viruses in addition to the negative-sense viruses already tested. 
Similarly, knockdown of IRF9 increased the number of infected 
cells and the relative number of viral transcripts produced to a 
similar extent as did MAVS knockdown when compared with 
siNeg cells, for both RSV and PIV (Fig.  6, C–F). Collectively, 
these data indicate that IRF9 deficiency leads to a broad defect 
in cell-intrinsic immunity to viruses in vitro. Altogether, these 
data strongly suggest that inherited IRF9 deficiency underlies 
P’s impaired immunity to influenza infection and her subse-
quent hospitalization for ARDS.
Discussion
We herein describe AR, complete IRF9 deficiency in a child with 
life-threatening influenza. Our data establish a causal relation-
ship between IRF9 deficiency and this patient’s severe pulmonary 
influenza (Casanova et al., 2014). Following autosomal dominant 
GATA2 deficiency and AR IRF7 deficiency, AR IRF9 deficiency is 
the third described single-gene inborn error of immunity that 
can underlie life-threatening influenza pneumonitis (Casanova, 
2015a,b; Ciancanelli et al., 2016). In contrast to IRF7 deficiency, 
which disrupts the amplification of antiviral IFNs, especially in 
pDCs, which are the only cells expressing high constitutive lev-
els of IRF7 (Ciancanelli et al., 2015), IRF9 deficiency results in 
an inability of all cell types to respond fully and effectively to 
type I IFNs, and by inference type III IFNs. The mechanistic con-
nection between IRF7 and IRF9 deficiency in humans suggests 
Figure 6. IRF9 is required for optimal con-
trol of viral infections. (A) WB confirms the 
efficiency of RNAi of IRF9 or MAVS in primary 
dermal fibroblasts. (B–F) Primary human dermal 
fibroblasts previously transfected with the indi-
cated siRNA (negative control, IRF9, MAVS) were 
tested for control of HRV, RSV, and PIV. Cells 
were infected with HRV-A16 at MOI of 10 (B), 
RSV at MOI of 0.5 (C and D), or PIV3 at MOI of 0.1 
(E and F). Relative HRV transcripts (B) were mea-
sured by qRT-PCR, and values were normalized 
to the siNeg control. Percentage of infected cells 
(C and E) and relative virus per infected cell (D 
and F) were measured by flow cytometric anal-
ysis of GFP+ cells. MFI of GFP+ cells in individual 
samples were normalized to negative control at 
24 h (D and F). Shown are the mean ± SD of six 
(B–F) experiments. *, P < 0.05; **, P < 0.01, by 
Kruskal-Wallis test.
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that the type I and III IFN responses driven by IRF7 amplifica-
tion and mediated by IRF9 signaling are essential for defense 
against influenza virus. However, patients with other defects in 
type I and/or III IFN signaling pathway, including deficiency of 
STAT1, STAT2, JAK1, TYK2, IFN AR2, and IL10RB, have not been 
reported to have suffered from severe influenza (Boisson-Dupuis 
et al., 2012; Hambleton et al., 2013; Engelhardt and Grimbacher, 
2014; Duncan et al., 2015; Kreins et al., 2015; Shahni et al., 2015; 
Eletto et al., 2016; Moens et al., 2017). This is perhaps because 
(1) they died of other severe infections before exposure to in-
fluenza virus, (2) the virus can be controlled independently of 
these signaling proteins, (3) at least some type I IFNs can signal 
without these proteins (de Weerd et al., 2013), or (4) the defect is 
partial, as opposed to complete, due to the hypomorphic nature 
of some mutant alleles (Chapgier et al., 2006; Hambleton et al., 
2013; Duncan et al., 2015). Alternatively, IRF9 and IRF7, unlike 
the other five genes, might regulate transcription of a key sub-
set of ISGs that specifically mediate immunity to influenza virus 
following type I and III IFN stimulation. A patient with IFN AR1 
deficiency was recently reported, yet his additional defect of IFN 
GR2 prevents conclusions to be drawn as to the mechanism of 
infectious phenotypes (Hoyos-Bachiloglu et al., 2017). A clearer 
picture of the contributions of these genes to human protective 
immunity to influenza virus will emerge as more inborn errors 
are discovered and as more patients are diagnosed.
Significantly, our IRF9-deficient patient was not hospitalized 
in the ICU following infection with RSV or HRV, both of which 
were confirmed by serology and VirScan, indicating that IRF9 
deficiency may not result in an extensive susceptibility to pul-
monary viral infections. This contrasts with an MDA5-deficient 
child who was prone to severe, recurrent rhinovirus infections 
(Lamborn et al., 2017), and other MDA5-mutated children who 
were prone to RSV and other severe viral infections of the re-
spiratory tract but not influenza (Asgari et al., 2017; Zaki et al., 
2017). Human MDA5 and IRF9 thus seem to control different sets 
of respiratory viruses in vivo. Interestingly, IRF7 deficiency may 
also result in a narrow infectious phenotype, as the only reported 
case in humans was uniquely susceptible to influenza infection 
at last follow-up, aged 9 yr, and without any prophylaxis other 
than annual influenza vaccination (Ciancanelli et al., 2015; un-
published data). IRF9 deficiency results in a slightly broader 
infectious phenotype, including infection with influenza virus 
and likely an MMR vaccine-strain virus. The phenotype might 
have been broader if the patient had not been started on IgG i.v. at 
2.5 yr of age. However, IRF9 deficiency is clinically closer to IRF7 
deficiency when compared with GATA2 deficiency. Indeed, all 
known patients with the latter defect suffered from many other 
severe infections, including mycobacterial infections, papilloma 
virus infections, blastomycosis, and repeated viral infections of 
the respiratory tract (Collin et al., 2015). Severe influenza was the 
presenting feature in only one patient, who quickly thereafter 
displayed other phenotypes, infectious and otherwise (Sologuren 
et al., 2018). This broad infectious phenotype is consistent with 
the broad immunological phenotype of GATA2 deficiency, which 
is not restricted to a lack of development of type I and III IFN-pro-
ducing pDCs. With the reservations listed above, it is striking that 
both IRF7 and IRF9 deficiency underlie such a narrow range of se-
vere infections, almost limited to severe influenza pneumonitis. 
Significantly, only single cases of IRF7 and IRF9 deficiency have 
been reported thus far; further studies are needed to more com-
prehensively define the viral susceptibility resulting from these 
deficiencies, to determine to what extent IRF7- and IRF9-depen-
dent type I and III IFN immunity is redundant for protective im-
munity against viral infections, and to suggest what other factors 
may compensate for deficiencies in this pathway.
Among patients with defects in the type I and/or III IFN sig-
naling pathways, complications from MMR vaccine have been 
reported in patients with IFN AR2, STAT1, or STAT2 bi-allelic mu-
tations (Hambleton et al., 2013; Duncan et al., 2015; Burns et al., 
2016; Moens et al., 2017). Although relatively rare in STAT1-defi-
cient individuals, a vaccine-strain MMR infection was reported 
in the only individual with AR complete STAT1 deficiency who 
was vaccinated (Burns et al., 2016). It is unclear whether pa-
tients with STAT2 and IFN AR2 deficiency have a complete or 
partial deficiency (Hambleton et al., 2013; Duncan et al., 2015; 
Moens et al., 2017). Interestingly, MMR vaccine complications 
were not observed in patients with AR partial STAT1 deficiency, 
nor have they been reported in patients with partial JAK1 or com-
plete TYK2 deficiency who were vaccinated (Boisson-Dupuis et 
al., 2012; Kreins et al., 2015; Eletto et al., 2016). This suggests a 
possible divergence from mice, where STAT1 is dispensable but 
STAT2 is not, for protection against measles virus (Hahm et al., 
2005; O’Donnell et al., 2012). The most parsimonious theory 
explaining these observations is that STAT2 and IRF9 mediate a 
physiologically relevant branch of the type I and III IFN signaling 
pathway in mice independently of STAT1, while some subset of 
this branch is dependent on STAT1 signaling in humans. STAT2-
IRF9 complexes have been described in both mice and humans, 
but it is unclear if they could drive the cellular changes required 
for defense against viral infection (Lou et al., 2009; Abdul-Sater 
et al., 2015). Of note, in our mRNA-seq analysis, we observed 
up-regulation of STAT2 in P's primary fibroblasts and B-LCL in 
response to IFN-α2b stimulation in vitro, perhaps not coinciden-
tally and consistent with nonredundant roles for STAT2 and IRF9 
in immunity to measles infection (Hambleton et al., 2013). These 
results add to evidence in mice that the different components 
of the ISGF3 complex regulate distinct, nonredundant subsets 
of ISGs in addition to a jointly regulated core of genes (Li et al., 
2017). Alternatively, the different MMR phenotypes in patients 
with various inborn errors of type I and III IFN immunity may 
merely reflect the impact of modifiers or of the environment it-
self, including the MMR inoculum. Ultimately, the experiment of 
nature deciphered in this report reveals the nonredundant roles 
of human IRF9 in the type I and/or III IFN signaling pathways for 




Whole blood, serum, and skin biopsies were obtained from the 
patient, her relatives, or paid healthy volunteers. These individ-
uals gave written informed consent to participate in research 
protocols approved by the Institutional Review Boards at The 
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Rockefeller University or the National Institute of Allergy and 
Infectious Diseases, National Institutes of Health.
Case report
We report the case of a girl born in 2013 to consanguineous par-
ents (first cousins, f = 1/16) of Algerian descent, living in France, 
who was admitted to intensive care with acute respiratory dis-
tress secondary to infection with IAV at the age of 23 mo. Accord-
ing to her medical history, she was born after 39 wk of gestation 
with a birth weight of 2,910 g, height of 47 cm, and Apgar score 
10/10. Her family history was negative for previous severe in-
fectious diseases.
Since the age of 5 mo, the patient had a history of recurrent 
fevers (3–5 d/mo) associated with digestive features including 
diarrhea, abdominal pain without any vomiting, transient cuta-
neous rash, and intermittent urticaria, initially suggestive of an 
auto-inflammatory syndrome since no infectious agent was iden-
tified. Prior to any supportive treatment, IL-1β and TNFα were 
positive, respectively, at 17.9 pg/ml (0–15) and 25.1 pg/ml (0–20), 
whereas IL-6 and IL-10 were normal and negative. MEFV, MVK, 
CIAS1, and TRA PS were sequenced and found without any dele-
terious variation. Anti c1q antibodies were consistently positive, 
but sequencing of DNA SE1L3 was normal.
She experienced five episodes of bronchiolitis revealing 
severe asthma (for which she was prescribed montelukast, al-
buterol, and ipratropium bromide), gingivostomatitis and ad-
enitis, and four episodes of prolonged gastroenteritis. She was 
hospitalized in the pediatric ICU (PICU) due to idiopathic biliary 
perforation 14 d after MMR vaccination at 16 mo old; dissemi-
nated intravascular coagulation was suspected secondary to 
thrombopenia (27,000/mm3) and low prothrombin time (40%), 
associated with elevated liver enzymes (SGOT 274 UI/l and SGPT 
128 UI/l). She was readmitted to the PICU 2 mo later with a sus-
picion of septic shock in the absence of a detectable pathogen, 
associated with elevated C-reactive protein (180 mg/l), lymph-
openia (830/mm3), low platelet count (14,000/mm3), and low 
prothrombin time (66%).
At 23 mo of age, she was admitted to the PICU with a severe 
influenza A infection resulting in ARDS requiring mechanical 
ventilation for 6 d. Because increased oxygen was required with 
continuous positive airway pressure (FiO2 100%), she was intu-
bated. She developed severe ARDS, with bilateral infiltrates on 
chest radiography. She was placed under mechanical ventilation 
in a volume support mode, with a frequency of 35 per minute 
and 100% FiO2. All bacteriological and viral sputum cultures were 
negative, except IAV. She was administered salbutamol, ipratro-
pium bromide, ketamine, theophylline, magnesium sulfate, cef-
triaxone, and oseltamivir. The oseltamivir treatment was stopped 
after 5 d. On the third day, bilateral parotidis and cervical adenitis 
appeared and were treated by amoxicillin and clavulanic acid. 
She was discharged from the PICU after 8 d, and her condition 
improved enough to be discharged after 22 d of hospitalization.
Standard immunological tests were performed. Serum levels 
of IgG, IgA, and IgM were unremarkable. T and natural killer 
lymphocyte count were conserved, whereas a modest B lympho-
cytosis was measured (Table S1). Lymphocyte proliferation was 
normal for PHA, tuberculin, and candidin (n > 50), but low in 
the presence of tetanus, CMV, and HSV antigens (n > 10; Table 
S2). T and B cell counts were within normal ranges. The pa-
tient was IgG seropositive for tetanus, diphtheria, haemophilus, 
measles, mumps, rubella, and HBV (Ag HBs negative, anti-HBs 
positive, anti-HBc negative) following routine vaccination. She 
remained seronegative for HIV1/2, HAV, HCV, VZV, Parvovirus 
B19, EBV, CMV, and pneumococcus despite proper vaccination 
for the latter.
Intravenous Igs at 0.4 g/kg/3 wk were begun at 2 yr 8 mo of 
age because of recurrent viral infections, resulting in an im-
provement of her recurrent fever profile, digestive symptoms, 
and susceptibility to viral infection.
Since i.v. Igs were started, the patient has been hospitalized 
on two occasions: once for acute respiratory distress secondary 
to metapneumovirus and once for febrile pseudo-occlusive syn-
drome with free fluid in Morrisson’s pouch detected by sonogram 
secondary to symptoms of gastroenteritis. At that time, RNA of 
parainfluenza 1,2,3,4 group was detected by PCR in the sputum, 
but no pathogen was detected known to cause gastroenteritis 
(also negative were rhinovirus/enterovirus, metapneumovirus, 
influenza A and B, coronavirus, and RSV A and B by PCR in the 
sputum and adenovirus, norovirus, enterovirus, and rotavirus 
by PCR in the stool). During neither episode was she admit-
ted to the PICU.
WES
Exome capture was performed with the SureSelect Human All 
Exon 50 Mb kit (Agilent Technologies). Paired-end sequencing 
was performed on a HiSeq 2000 (Illumina), generating 100-
base reads. We aligned the sequences with the GRCh39 refer-
ence build of the human genome using the BWA aligner (Li and 
Durbin, 2009). Downstream processing and variant calling were 
performed with the Genome Analysis Toolkit, SAMtools, and 
Picard (Li et al., 2009; McKenna et al., 2010). Substitution and 
InDel calls were made with the GATK Unified Genotyper. All vari-
ants were annotated using an annotation software system that 
was developed in-house (Ng and Henikoff, 2001; Adzhubei et al., 
2010; Kircher et al., 2014).
Genetics
WES analysis of the patient revealed a total of 15,807 variants in 
P. We filtered out all variations found in a 1,000-genome data-
base, the GnomAD, our own database of 4,892 exomes for infec-
tious diseases other than influenza at a frequency of >1%, leaving 
44 nonsynonymous coding variants in the patient’s exome: 20 
homozygous and 24 heterozygous (Table S3). The heterozygous 
variants inherited from one parent were not considered in a model 
of complete penetrance. Excepting four heterozygous and two ho-
mozygous variants, none of the variants affected genes related to 
immunity. The mutated IRF9 allele was not found in 1,046 genomic 
DNA samples from 52 ethnic groups (including French) from the 
HGDP-CEPH Human Diversity Panel. The missense c.991G>A mu-
tation had a CADD score of 32.21. A genomic measure of individual 
homozygosity was plotted for P, two European individuals from 
consanguineous families, and 37 individuals from nonconsanguin-
eous families from our in-house WES database. Homozygosity was 
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computed as the proportion of the autosomal genome belonging to 
runs of homozygosity (ROHs). The ROHs were defined as ranging 
at least 1 Mb of length and containing at least 100 single nucleotide 
polymorphisms (SNPs), and were estimated using the homozyg 
option of the PLI NK software (Purcell et al., 2007). The cen-
tromeres were excluded because they are long genomic stretches 
devoid of SNPs and their inclusion might inflate estimates of ho-
mozygosity if both flanking SNPs are homozygous. The length of 
the autosomal genome was fixed at 2,673,768 kbs as previously de-
scribed (McQuillan et al., 2008). We estimated the selective pres-
sure acting on IRF9 to be 0.088 (indicative of purifying selection) 
by estimating the neutrality index (Stoletzki and Eyre-Walker, 
2011) at the population level (PN/PS)/(DN/DS), where PN and 
PS are the number of nonsynonymous and synonymous alleles, 
respectively, at population level (1000 Genomes Project) and DN 
and DS are the number of nonsynonymous and synonymous fixed 
sites, respectively, for the coding sequence of IRF9.
Cells
PBMCs were isolated by Ficoll-Paque density gradient (Lymph-
oprep; Proteogenix) from the blood of the patient, the mother, 
and a healthy donor. SV40-immortalized dermal fibroblasts, 
U2A, Madin-Darby canine kidney, and Vero E6 cells were main-
tained in DMEM supplemented with 10% FBS. B-LCLs were 
grown in RPMI 1640 medium supplemented with 10% FBS. Sta-
bly transfected dermal fibroblasts were obtained by transfect-
ing pTRI PIRF9iresRFP using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. Stable transfectants 
were selected by puromycin treatment (0.3 μg/ml) and subse-
quent fluorescence-activated cell sorting for RFP-expressing 
cells yielding >80% RFP+ fibroblasts.
Plasmids
The cDNA of IRF9 was cloned into pGEMT cloning vector 
(Promega). Site-directed mutagenesis was performed to obtain 
the indicated mutant constructs. All IRF9 constructs were then 
subcloned into the pTRIP.CMV.IVSb.iresTagRFP_Dest vector 
using Gateway cloning technology (Life Technologies) and rese-
quenced to ensure no advantitious mutations were generated 
during the cloning.
Western blotting
Fibroblasts were pretreated with IFN-α2b (Schering) or IFN-γ 
(Imukin; Boehringer Ingelheim) for the specified times before 
lysis. Cells were lysed in NP-40 lysis buffer (280  mM NaCl, 
50  mM Tris, pH 8, 0.2  mM EDTA, 2  mM EGTA, 10% glycerol, 
0.5% NP-40) supplemented with 1 mM dithiothreitol, PhosSTOP 
(Roche), and Complete protease inhibitor cocktail (Roche). 20 
μg protein lysate per lane was resolved by SDS-PAGE and trans-
ferred to polyvinylidene fluoride membrane, which was probed 
with unconjugated primary antibodies and HRP-conjugated sec-
ondary antibodies. Anti-GAP DH (Santa Cruz Biotechnology) or 
anti-Lamin A/C (Santa Cruz Biotechnology) antibodies were used 
as loading controls. IRF9 was probed with antibody recognizing 
the C-terminus at a dilution of 1:1,000 (ISGF-3γ p48 [H10]; Santa 
Cruz Biotechnology). SuperSignal West Pico Chemiluminescent 
substrate (Thermo Fisher Scientific) was used to visualize HRP 
activity, and this signal was detected by an Amersham Imager 
600 (GE Life Sciences).
Knockdown efficiency was determined by immunoblotting. 
30 μg of total protein loaded per lane were separated on 4–12% 
NuPAGE Bis-Tris SDS-PAGE gels (Invitrogen) and then trans-
ferred onto nitrocellulose membranes using the Trans-Blot 
Turbo Transfer System (Bio-Rad Laboratories). After blocking 
with 5% nonfat dry milk (Bio-Rad Laboratories) in PBS contain-
ing 0.1% Tween 20 (Sigma-Aldrich), membranes were blotted 
with the IRF9 antibody (ISGF-3γ p48 [H10]), MAVS (clone 3993; 
Cell Signaling Technologies), or HSP90 (clone 68; BD Biosci-
ences), followed by incubation with appropriate HRP-conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratories) 
and SuperSignal West Pico Chemiluminescent substrate or 
SuperSignal West Dura Extended Duration Substrate (Thermo 
Fisher Scientific). Signal was detected by ChemiDocTM Touch 
Imaging System (Bio-Rad Laboratories).
EMSAs
EMSA was performed as previously described (Chapgier et al., 
2006). In brief, cell activation was blocked by incubation with 
cold 1× PBS, and the cells were gently lysed to remove cytoplasmic 
proteins while keeping the nucleus intact. Nuclear lysis buffer 
was then added, and the recovered nuclear extracts were sub-
jected to nondenaturing electrophoresis with Alexa 647–labeled 
GAS (from the FCγR1 promoter: 5′-ATG TAT TTC CCA GAAA-3′) and 
ISRE (from the ISG15 promoter: 5′-GAT CGG GAA AGG GAA ACC 
GAA ACT GAA-3′) probes. Gels were then imaged on an Amersham 
Imager 600 (GE Life Sciences) in the Cy5 channel.
Reporter assays
U2A cells were transfected with the indicated expression plas-
mids, firefly luciferase plasmids under the control of ISRE or 
GAS promoters, and a constitutively expressing Renilla firefly 
luciferase plasmid for normalization. 24  h after transfection, 
the cells were stimulated with IFN-α2b, -β, or -γ for 18  h or 
were left unstimulated. Luciferase levels were measured using 
Dual-Glo reagent according to the manufacturer’s protocol 
(Promega). Firefly luciferase values are normalized to Renilla 
luciferase values, and fold induction is expressed relative to un-
stimulated samples.
Exon trapping assays
U2A cells were transfected with pSPL3 plasmids containing a 
genomic region encompassing IRF9 exons 6 through 8 (WT or 
c.991G>A mutation). RNA was then purified from these cells, 
and the IRF9 splice products were amplified using flanking HIV-
TAT sequences in the pSPL3 vector. RNA was then reverse-tran-
scribed and ligated into the pGEM-T vector (Promega). DH5α 
cells (Thermo Fischer Scientific) were transformed with the re-
sulting plasmids, and colony PCR followed by sequencing of IRF9 
was performed to determine the splicing products produced by 
the mutated and WT alleles.
qRT-PCR
Total RNA from PBMCs was extracted using RNAqueous-Micro 
Kit (Ambio). Reverse transcription was performed using the 
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High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). Messenger RNAs were quantified with IRF9 probes 
Hs00960976-m1 (exon 1–2) and Hs00196051-m1 (exon 7–8; 
Thermo Fischer Scientific) by qRT-PCR using the Taqman Gene 
Expression Assay (Applied Biosystems) and normalized to the ex-
pression level of HPRT1. RNA was isolated from SV40-fibroblasts, 
and B-LCL cells were stimulated with 1,000 IU/ml IFN-α2b, IFN-
β, or IFN-γ for 2 or 8 h with RNA lysis buffer, treated with DNase, 
and purified according to the manufacturer’s protocol (Zymo 
Research). RT-PCR was performed using random hexamers and 
the Superscript III reverse strand synthesis kit according to the 
manufacturer’s instructions (Thermo Fisher Scientific). Quan-
titative real-time PCR was performed with Applied Biosystems 
Taqman assays using the β-glucuronidase housekeeping gene for 
normalization. Results are expressed using the ΔΔCt method, as 
described by the manufacturer.
Virus assays
IAV and VSV infections
SV40 fibroblasts were infected with influenza virus (A/Califor-
nia/4/2009) at a multiplicity of infection (MOI) of 0.5 (MOI = 
0.5). The inoculum was absorbed onto the cells for 30 min at 
25°C. Cells were washed twice with Hank’s balanced salt solution 
and cultured at 37°C in the presence of 0.1 µg/ml TPCK-treated 
trypsin (Sigma-Aldrich). Virus samples were collected at the in-
dicated times after infection. Influenza titers were determined 
by plaque assay on Madin-Darby canine kidney cells. Fibroblasts 
were infected with VSV at MOI = 3. The inoculum was absorbed 
onto the cells for 30 min at 25°C, washed twice with PBS, and cul-
tured in DMEM 10% FBS at 37°C. Virus samples were collected at 
indicated time points. Viral titers were determined by endpoint 
dilution on Vero cells using the Reed and Muench calculation. 
Where indicated, cells were pretreated with IFN-α2b for 16 h be-
fore virus infection.
RSV, PIV, and HRV infections
HRV-A16 and recombinant RSV derived from the A2 strain and 
containing the enhanced GFP were used as previously described 
(Lamborn et al., 2017). rgPIV3, a recombinant human PIV type 
3 derived from the JS strain and containing the enhanced GFP, 
was a gift from Dr. P. Collins, National Institute of Allergy and 
Infectious Diseases (Zhang et al., 2005). SV40-transformed fi-
broblasts were seeded at 100,000 cells per well in 12-well tissue 
culture plates in DMEM supplemented with 10% FBS, 2  mM 
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (all 
from Invitrogen), and 55 µM 2-ME (Sigma-Aldrich). After over-
night culture, cells were infected with RSV-GFP (MOI = 0.5) or 
PIV3-GFP (MOI = 0.1). At 24 and 48 h after infection, cells were 
harvested, and flow cytometric detection of GFP in RSV-infected 
viable cells was performed as previously described (Lamborn et 
al., 2017). Flow cytometric detection of GFP in PIV3-infected via-
ble cells was performed under similar conditions. For IRF9 siRNA 
knockdown experiments, human primary dermal fibroblasts 
were transfected with negative siRNA control, Stealth siRNA to 
IRF9 (HSS173591; Thermo Fisher Scientific), or siRNA to MAVS 
(HSS148537; Thermo Fisher Scientific), using the P3 Primary Cell 
96-well Nucleofector kit (Lonza) as described (Lamborn et al., 
2017). 3 d after transfection, cells were infected with RSV (MOI 
= 0.5), PIV (MOI = 0.1), or HRV16 (MOI = 10). RSV, PIV, and HRV 
replication was quantitated as described above.
VirScan analysis
Patient serum was analyzed by VirScan in two independent ex-
periments as previously described (Xu et al., 2015). Briefly, an 
oligonucleotide library encoding 56 amino acid peptides tiling 
across the genomes of 206 viral species was synthesized on a re-
leasable DNA microarray and cloned into T7 phage. Patient serum 
containing 2 μg of IgG was added to the phage library, and im-
munoprecipitation was performed with Protein A and G beads. 
Enriched peptides were identified by PCR and Illumina sequenc-
ing of the peptide cassette from the immunoprecipitated phage.
Statistical analyses
For viral replication, the Prism 7 software (GraphPad) was used 
to calculate P values using one-way ANO VA with Dunnett’s 
multiple comparisons, Kruskal-Wallis test with Dunn’s multi-
ple comparisons.
mRNA-seq analysis
Total RNA from IFN-α2b–stimulated B-LCL and primary fibro-
blast cells was isolated (RNeasy kit; QIA GEN), and RNA integrity 
was assessed on an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies). Poly (A)mRNA enrichment and cDNA library preparation 
was performed using a TruSeq Stranded mRNA Library Prep Kit 
(Illumina) in accordance with the manufacturer’s recommen-
dations. Paired-end sequencing was performed on a HiSeq4000 
(Illumina) with 150 cycles. Quality control of the raw Fastq files 
was performed using FastQC (Andrews, 2010). The samples were 
then aligned to the reference genome (Ensembl GRCh37) using a 
STAR aligner (Dobin et al., 2013). Aligned output was then con-
verted to BAM files using SAMtools (Li et al., 2009). The resulting 
BAM files were used to quantify the read counts using the HTseq-
count tool (Anders et al., 2015). The output of technical repeats 
(patient samples that had been stimulated in duplicate) was 
found to have a high correlation coefficient (not shown). Sub-
sequent downstream analysis was performed in the R statistical 
programming language (Team, 2008). Read counts of technical 
repeats were averaged, and IFN-α2b–responsive transcripts were 
identified by comparing stimulated against unstimulated condi-
tions in the three healthy control subjects, using a minimal 1.5-
fold change in expression (up-regulated or down-regulated) as 
the cut-off. The response gene lists only those that had satisfied 
the filter criteria in all three controls. This resulted in a total of 
1,064 and 1,576 genes that were responsive in the IFN-α2b–stim-
ulated B-LCL and primary fibroblasts, respectively. The gene lists 
were then used to identify, again using a 1.5-fold change as cut-
off, IFN-α2b–responsive and unresponsive genes in the cells of 
IRF9-, STAT1-, and STAT2-deficient patients. The overall residual 
responses in the patient’s cells were computed by counting the 
responsive genes in each patient and cell type and by calculat-
ing the percentage out of the total number of response genes in 
each cell type. The response in the healthy control subject was set 
at 100%. We used MS Excel to filter for response genes that are 
common or unique to specific patients for subsequent analysis.
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For B-LCL network analysis, a greater than fivefold cut-off 
was applied to the control groups to generate the target list of 
IFN-α2b–induced genes. From the 749 up-regulated genes in the 
healthy controls, 84 were induced at > fivefold. This gene was 
then used to filter the IRF9-deficient patient, using the same >1.5-
fold cut-off applied in RNA-seq analysis. In the IRF9-deficient 
patient, a total of 37 genes were found to be induced at >1.5-fold, 
and 47 were nonresponsive. These two lists were then entered 
into Interferome v2.01 and queried for ISGs, using similar experi-
mental criteria as the current study (Rusinova et al., 2013). Of the 
37 genes found to be responsive in the IRF9-deficient patient, 24 
were identified as ISGs. Of the 47 nonresponsive genes, 39 were 
identified as ISGs. The combined ISG gene lists for the IRF9-de-
ficient patient was used to conduct network analysis in Gene-
MAN IA, using biological process based Gene Ontology weighting 
method and the maximum resultant genes set to 20 (Warde-
Farley et al., 2010). The network was examined using both bio-
logical pathway (4.35%) and physical interactions (67.64%).
Data availability
mRNA-seq data have been deposited to GEO and are available 
under accession no. GSE117637.
Online supplemental material
Fig. S1 shows antibodies against viruses that were detected by 
VirScan analysis of the IRF9-deficient patient’s sera. Fig. S2 dis-
plays the PCR scheme used in exon trapping experiments. Table 
S1 presents the immunophenotyping results of the IRF9-defi-
cient patient. Table S2 demonstrates the proliferation of the 
IRF9-deficient patient’s CD4+ T cells in response to various stim-
uli. Table S3 catalogs the rare, biallelic mutations present in the 
IRF9-deficient patient. 
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